Compare Amphastar Pharmaceuticals Inc (AMPH) vs Sea Limited (SE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Sea Limited (SE) trades at $111.14, up 1.86% on the day, near its resistance level of $112. The stock shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Technical indicators are bullish on moving averages but show overbought conditions with RSI above 78. Analyst sentiment remains positive with a consensus price target of $131.

Outlook: Growth prospects are supported by expanding digital services in Southeast Asia, but risks include competitive pressures and execution challenges. The stock's high P/E of 43.76 suggests premium valuation, requiring sustained earnings growth to justify current levels. Near-term performance may hinge on Q2 2026 earnings versus expectations of $0.834 EPS.